LIBATEC®
LIBATEC® is Wacker Biotech’s technology platform for developing and manufacturing Live Biotherapeutic Products (LBPs). We developed LIBATEC® to meet our customers’ growing need for LBPs, both for clinical and market supply. Customers of the LIBATEC® platform benefit from our wealth of experience in developing and optimizing LBP processes and in GMP production.
Wacker Biotech has already manufactured a wide range of LBPs, including wild-type and genetically modified strains for use as live biotherapeutics, vaccines, immunotherapy and delivery systems for clinical and commercial use.
The LIBATEC® platform is ideal for manufacturing without hold times, and for maintaining the cell viability throughout the production process.
Advantages:
- Over a decade of experience in LBP development and manufacturing
- Fermentation regimes for aerobic and specific anaerobic organisms
- Optimization of upstream and downstream processes
- GMP-compliant drug substance manufacturing on various fermentation scales up to 1,500 liters, with integrated drug product production, including lyophilization
- Closed production systems (monoseptic processing) in order to maintain culture purity, crucial to meeting customers’ and regulators’ quality requirements
